|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-3-13
|
|
pubmed:abstractText |
The mortality risk associated with attempting to raise hemoglobin (Hb) levels by increasing Epoetin alfa (EPO) doses in hemodialysis patients with persistently low Hb remains poorly understood. Design, setting, participants, & measurements. We included hemodialysis patients from a large dialysis provider between July 2000 and June 2001 who had EPO dose and Hb data for 6 consecutive months, and a mean Hb <11 g/dl in months 4 to 6 (sub-11 period). We identify predictors of EPO dose changes during the sub-11 period; evaluate the proportion of patients achieving a Hb >or=11 g/dl after the sub-11 period by dose-change categories; and evaluate the association between EPO dose changes and mortality risk.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-11803162,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-12500228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-15492953,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-15528060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-15569336,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-15696453,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-15824128,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-16129210,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-16221236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-16377395,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-16377399,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-16449284,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-16565261,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-16984328,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-17108343,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-17210593,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-17699392,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-18045862,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-18155534,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-18417744,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-9718377,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19261826-9915269
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1555-905X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
630-7
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19261826-Adult,
pubmed-meshheading:19261826-Aged,
pubmed-meshheading:19261826-Anemia, Iron-Deficiency,
pubmed-meshheading:19261826-Biological Markers,
pubmed-meshheading:19261826-Erythropoietin,
pubmed-meshheading:19261826-Female,
pubmed-meshheading:19261826-Hematinics,
pubmed-meshheading:19261826-Hemoglobins,
pubmed-meshheading:19261826-Humans,
pubmed-meshheading:19261826-Kaplan-Meier Estimate,
pubmed-meshheading:19261826-Kidney Diseases,
pubmed-meshheading:19261826-Male,
pubmed-meshheading:19261826-Middle Aged,
pubmed-meshheading:19261826-Proportional Hazards Models,
pubmed-meshheading:19261826-Recombinant Proteins,
pubmed-meshheading:19261826-Renal Dialysis,
pubmed-meshheading:19261826-Retrospective Studies,
pubmed-meshheading:19261826-Risk Assessment,
pubmed-meshheading:19261826-Risk Factors,
pubmed-meshheading:19261826-Time Factors,
pubmed-meshheading:19261826-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.
|
|
pubmed:affiliation |
Department of Biostatistics and Epidemiology, Amgen, Inc, Thousand Oaks, California 41984, USA. bradbury@amgen.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
